Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | FAAH | O00519 | 3/20 | 0.43 |
| ▸ | MME | P08473 | 2/20 | 0.42 |
| ▸ | ACE | P12821 | 1/20 | 0.42 |
| ▸ | CPA1 | P15085 | 1/20 | 0.42 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | CTSC | P53634 | 1/20 | 0.41 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.41 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3145911 | 1.00 | SMN1; SMN2 (0.50) | SMN1; SMN2ALDH1A1KDM4EMAPTFAAH | |
| SCHEMBL783990 | 1.00 | SMN1; SMN2 (0.50) | SMN1; SMN2ALDH1A1KDM4EMAPTFAAH | |
| Hydrochloric Acid SCHEMBL12095469 | 0.98 | SMN1; SMN2 (0.49) | SMN1; SMN2ALDH1A1KDM4EMAPTFAAH | |
| Hydrochloric Acid SCHEMBL2487054 | 0.98 | SMN1; SMN2 (0.49) | SMN1; SMN2ALDH1A1KDM4EMAPTFAAH | |
| SCHEMBL24323603 | 0.92 | MME (0.46) | SMN1; SMN2ALDH1A1KDM4EMAPTFAAH | |
| SCHEMBL10621114 | 0.92 | MME (0.46) | SMN1; SMN2ALDH1A1KDM4EMAPTFAAH | |
| SCHEMBL31106850 | 0.92 | MME (0.46) | SMN1; SMN2ALDH1A1KDM4EMAPTFAAH | |
| SCHEMBL31106917 | 0.92 | MME (0.46) | SMN1; SMN2ALDH1A1KDM4EMAPTFAAH | |
| SCHEMBL30905102 | 0.92 | MME (0.46) | SMN1; SMN2ALDH1A1KDM4EMAPTFAAH | |
| SCHEMBL29384229 | 0.92 | MME (0.46) | SMN1; SMN2ALDH1A1KDM4EMAPTFAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1645 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122080307-A | Emulsion for fracturing fluid suitable for bio-gel flowback fluid and preparation method thereof | — | 2026-05-26 | — | — | CN | claimed |
| WO-2026107097-A1 | SELF-IMMOLATIVE LINKERS AND CONJUGATES THEREOF | ENLAZA THERAPEUTICS, INC. (US) | 2026-05-21 | — | — | WO | claimed |
| EP-4504166-B1 | TOPICAL FORMULATION FOR USE IN THE TREATMENT OR PREVENTION OF ITCHY DRY SKIN | MC2 THERAPEUTICS LTD (GB) | 2026-04-29 | — | — | EP | claimed |
| US-20260103700-A1 | REGULATION OF RAN TRANSLATION BY PKR AND EIF2A-P PATHWAYS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2026-04-16 | — | — | US | claimed |
| EP-4719498-A1 | RADIOLIGANDS FOR TARGETING CELL SURFACE RECEPTORS AND USES THEREOF | Full-Life Technologies UK Limited (GB) | 2026-04-08 | — | — | EP | claimed |
| EP-4719486-A1 | CONJUGATES AND USES THEREOF | Full-Life Technologies UK Limited (GB) | 2026-04-08 | — | — | EP | claimed |
| US-20250375466-A1 | MANIPULATION OF EIF3 TO MODULATE REPEAT ASSOCIATED NON-ATG (RAN) TRANSLATION | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2025-12-11 | — | — | US | claimed |
| EP-4659591-A1 | TASTE-ENHANCING COMPOSITION, METHOD FOR PRODUCING SAME, FOOD PRODUCT, AND METHOD FOR ENHANCING TASTE OF FOOD PRODUCT | House Foods Group Inc. (JP) | 2025-12-10 | — | — | EP | claimed |
| EP-4659592-A1 | FLAVOR ENHANCING COMPOSITION, MANUFACTURING METHOD THEREFOR, AND METHOD FOR ENHANCING FLAVOR OF FOOD PRODUCT | House Foods Corporation (JP) | 2025-12-10 | — | — | EP | claimed |
| EP-4649087-A2 | NON-VIRAL EXPRESSION SYSTEMS AND METHODS OF USE THEREOF | Engage Biologics Inc. (US) | 2025-11-19 | — | — | EP | claimed |
| US-5126245-A | REAGENTS FOR ASSAY OF GAMMA-GLUTAMYLTRANSPEPTIDASE | UNITIKA LTD. (JP) | 1992-06-30 | — | — | US | claimed |
| EP-0266905-B1 | REAGENTS FOR ASSAY OF GAMMA-GLUTAMYL-TRANSPEPTIDASE | UNITIKA LTD. (JP) | 1992-04-15 | — | — | EP | claimed |
| EP-0226304-B1 | COMPOSITION CONTAINING A PENEM OR CARBAPENEM ANTIBIOTIC | SANKYO COMPANY LIMITED (JP) | 1991-08-28 | — | — | EP | claimed |
| US-4980035-A | Bath for electrolytic deposition of a gold-copper-zinc alloy | ENGELHARD CORPORATION (US) | 1990-12-25 | — | — | US | claimed |
| US-4810656-A | MEDICAL DIAGNOSIS | CHEMICAL LABORATORIES S.R.L. (IT) | 1989-03-07 | — | — | US | claimed |
| EP-0304315-A1 | Bath for electrolytic deposition of a gold-copper-zinc alloy | ENGELHARD LIMITED (GB) | 1989-02-22 | — | — | EP | claimed |
| US-4757066-A | Reduces renal toxicity | SANKYO COMPANY LIMITED (JP) | 1988-07-12 | — | — | US | claimed |
| EP-0266905-A1 | Reagents for assay of gamma-glutamyl-transpeptidase | UNITIKA LTD. (JP) | 1988-05-11 | — | — | EP | claimed |
| EP-0226304-A1 | Composition containing a penem or carbapenem antibiotic | SANKYO COMPANY LIMITED (JP) | 1987-06-24 | — | — | EP | claimed |
| CN-86107574-A | Compositions containing penem or carbapenem antibiotics and their use | — | 1987-05-20 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260103700-A1 | REGULATION OF RAN TRANSLATION BY PKR AND EIF2A-P PATHWAYS | EIF2A, EIF2AK1, EIF2AK3 | SMN1; SMN2 568/4885ALDH1A1 4874/4885KDM4E 1622/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.